China just cut rates and is subsidizing mortgages — go long Chinese large-caps on the stimulus push

Verdict: The stimulus thesis is plausible, but nothing has confirmed yet — wait

The strongest point for this trade is the September 29, 2026 Reuters-reported stimulus package — a coordinated rate cut plus mortgage subsidies — landing on Chinese equities that BABA's 8.1% revenue growth to $148.4B and 63rd-percentile operating margin show are profitable, not distressed. The strongest point against is that the anchor fundamentals are deteriorating sharply: operating margin fell from 14.1% to 4.9%, operating cash flow halved to $11.0B, the dividend was cut 47.5% to $1.05 per share, and insiders were net open-market sellers of about $72.4M for the quarter ended June 30, 2026. The completed backtest is thin and unconvincing — 4 trades over 60 months, a 50% win rate, just a 5.6% return against a 20.5% maximum drawdown, and the last 12 months lost 5.1% — and no robust parameter setup was established because the sensitivity evaluation exceeded its time budget. Live confirmation is absent too: FXI's RSI sits at 36.2 versus the 45 trigger, ADX near 16 versus 25, and price must reclaim the $34.56 EMA-20 before the entry checklist can complete. The verdict flips if BABA's next quarterly print (due around early November) shows margin stabilization alongside an FXI reclaim of $34.56 and the RSI cross above 45; until then, the policy flow is carrying all the weight while informed money leans the other way.

Trade now

Nothing is triggered today — this is a wait-for-confirmation setup, and the wait is defined, not vague. FXI closed at $33.77, MCHI at $51.94, and BABA at $107.91. Each name carries the identical entry checklist: price back above its 20-day EMA, above the 50-day EMA, a cross of the 14-day RSI above 45, and a 14-day ADX above 25, with price still inside the Bollinger band. Right now only the Bollinger condition is met on all three. The momentum conditions are furthest away: FXI's RSI is 36.2 and needs to cross above 45, MCHI's is 30.2, and BABA's is 35.2. ADX sits near 16 across the board against a 25 threshold — the trend strength simply isn't there yet. The nearer conditions are price conditions. FXI needs to regain its 20-day EMA at $34.56 (about 2.3% above the last close) and its 50-day EMA at $34.88; MCHI needs $53.34 and $53.90; BABA needs $112.14 and $115.04, roughly 3.9% and 6.6% above the last close. In practice, a sustained rally that reclaims the 20-day EMA is the fastest path, but the RSI cross above 45 usually needs a few more up days behind it. "Wait" means holding off until all five conditions line up — the strategy's own backtest over five years shows 50% winners on 4 trades with a 5.6% return and a 20.5% max drawdown, so entry quality matters. Once in, risk is mechanical: a stop at a 2.5% loss on the position, a take-profit near 5%, and an additional momentum-failure exit if price closes back below the 20-day EMA. Positions are capped at 25% of capital with roughly 2.5% risk per trade. If price keeps falling instead of reclaiming those moving averages, there is no trade — that's the design working, not a reason to force an entry.

Stimulus-Driven Re-Rating Meets a Backtest That Actually Traded

The idea's core argument — that a coordinated China rate cut plus mortgage subsidies (per the September 29, 2026 Reuters report) can trigger a re-rating of deeply out-of-favor Chinese large caps — is a policy-divergence thesis, and the completed backtest gives it a real, if modest, footing. Over the longest evaluated window (60 months on FXI, daily bars), the strategy returned 5.6% across 4 trades with a 50% win rate, and the equity curve shows exactly the pattern the thesis predicts: a sharp policy-driven burst in early 2023 (from roughly -3.8% to +9.8%) and again in the February–October 2025 stretch, where gains compounded to +32.8% before fading. Those are the moments when Chinese assets re-rated on stimulus headlines. The fundamental picture for the group's anchor name, Alibaba (BABA), does not contradict a demand-recovery bet on China large caps. Revenue grew 8.1% year over year to $148.4B for the fiscal year ended March 31, 2026, and gross margin held essentially flat at 39.8% versus 40.0% a year earlier — after recovering from the 36.7% troughs of 2022–2023. The company still generated $15.0B of net income and sits on $19.1B of cash against $113.6B of total liabilities with a 1.28 current ratio. Against 803 Information Technology peers, BABA ranks in the 63rd percentile on operating margin and the 66th percentile on return on equity — this is not a distressed name; it is a profitable one that policy easing can re-rate. The dividend track record also cuts both ways, but for the bull case it shows shareholder return is a live policy: BABA paid $1.05 per share with a June 11, 2026 ex-date. It is a cut from the prior $2.00, but the cash is still flowing, and a stimulus-led earnings recovery (net income fell 16.2% year over year to $15.0B) gives room to rebuild it. The tactical design supports the thesis rather than fighting it. The rule set requires price above the 50-day average, a bullish RSI crossing above 45, and trend strength (ADX above 25) before entering — it waits for the re-rating to confirm rather than front-running it. The 2.5% stop, 5% take-profit, and 90-bar time stop cap the cost of being early on a policy call that can take months to land. Finally, using FXI and MCHI alongside BABA means the position captures the broad large-cap re-rating the idea describes, without betting everything on one name — though FXI and MCHI issuer fundamentals are not yet ingested, so the ETF-level bull case rests on the backtest and the policy catalyst rather than…

Scores

• Conviction score breakdown: 39
• Thesis support: 55
• Trade readiness: 30
• Risk quality: 45
• Backtest evidence: 35
• Fundamentals trend: 30

Watch items

• FXI — Price vs 20-day EMA
• MCHI — Price vs 20-day EMA
• BABA — Price vs 20-day EMA
• FXI — RSI (14)
• MCHI — RSI (14)
• BABA — RSI (14)
• FXI — ADX (14)
• MCHI — ADX (14)
• BABA — ADX (14)
• BABA — Insider open-market net value
• BABA — Operating margin
• BABA — Annual dividend per share